Despite 12 Percent Drop in Q1 Sales, Meridian Bioscience Maintains Positive FY '11 Outlook

Meridian maintained its guidance for fiscal year 2011 based in part on the gradual uptake of its Illumigene amplification-based C. difficile test and positive contributions from its recently acquired Bioline business.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.